References
Mahoney KM, Rennert PD, Freeman GJ (2015) Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14:561–584
Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, Csaky KG, Rosenberg SA (2004) Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 27:478–479
Leo M, Maggi F, Rotondo Dottore G, Casini G, Mazzetti P, Pistello M, Sellari-Franceschini S, Nardi M, Vitti P, Marcocci C, Marinò M (2017) Graves’ orbitopathy, idiopathic orbital inflammatory pseudotumor and Epstein–Barr virus infection: a serological and molecular study. J Endocrinol Invest 40:499–503
Li HX, Xiang N, Hu WK, Jiao XL (2016) Relation between therapy options for Graves’ disease and the course of Graves’ ophthalmopathy: a systematic review and meta-analysis. J Endocrinol Invest 39:1225–1233
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All diagnostic and therapeutic procedures performed in this study were in accordance with ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from the individual participant included in the study.
Rights and permissions
About this article
Cite this article
Sabini, E., Sframeli, A. & Marinò, M. A case of drug-induced Graves’ Orbitopathy after combination therapy with Tremelimumab and Durvalumab. J Endocrinol Invest 41, 877–878 (2018). https://doi.org/10.1007/s40618-018-0906-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-018-0906-0